StockData
Bluejay Diagnostics, Inc. logo

Bluejay Diagnostics, Inc. (BJDX) stock

BJDXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$2.61+0.00 (+0.19%)

Close on Nov 13, 2026Market cap $2.92MP/E –Yield –

Bluejay Diagnostics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Bluejay Diagnostics's ebitda for the twelve months ending Dec 31, 2022 was -$9.16M. For fiscal 2022 it was -$9.16M.

Annual ebitda

PeriodPeriod endValueChange
FY2022Dec 31, 2022-$9.16M–
FY2021Dec 31, 2021-$3.08M–
FY2020Dec 31, 2020-$1.04M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2022Dec 31, 2022-$2.42M–
Q3 FY2022Sep 30, 2022-$2.77M–
Q2 FY2022Jun 30, 2022-$1.94M–
Q1 FY2022Mar 31, 2022-$2.03M–
Q4 FY2021Dec 31, 2021-$1.33M–
Q3 FY2021Sep 30, 2021-$919.85K–
Q2 FY2021Jun 30, 2021-$638.53K–
Q1 FY2021Mar 31, 2021-$192.37K–
Q4 FY2020Dec 31, 2020-$535.88K–

More Bluejay Diagnostics figures

See a number that looks wrong?